al. 2008). Although substantial advances in biomedical science and public health have facilitated the control of numerous infectious diseases over the past century, the world has witnessed an increasing incidence and geographical expansion of emerging and re-emerging infectious diseases (Jones et al. 2008 , Yang et al. 2012 . Discovering new antimicrobial agents is important because several pathogenic microorganisms have acquired resistance. The prevalence of Staphylococcus aureus strains that are resistant to conventional antibiotics has greatly increased in some hospitals (Fluit et al. 2001 , Hidron et al. 2008 , Rosenthal et al. 2010 .
There has been an increase in the number of immunocompromised hosts because of advances in medical technology and the human immunodeficiency virus pandemic (Wills et al. 2000) and the risk for opportunistic fungal infections has greatly increased in these patients. Moreover, common pathogens and new pathogenic species that possess intrinsic primary resistance are rapidly developing secondary resistance to the current antifungal agents (White et al. 1998) . Other diseases, such as paracoccidioidomycosis (PCM), require long-term therapy to ensure a good clinical response and to avoid a relapse. Importantly, long periods of treatment, which are typically required to control these types of fungal infections, are correlated with drug toxicity, high costs and treatment abandonment by the patients. Relapse is a significant obstacle for patients and those patients who do not respond and severely ill patients pose a problem for conventional therapeutic approaches (Brummer et al. 1993 , Coutinho et al. 2002 , Paniago et al. 2003 , Travassos et al. 2008 . The increase in antibacterial resistance and the restricted number of commercially available antifungal drugs emphasise the need for the development of novel and more effective antifungal and antibacterial agents.
In this work, we evaluated the antimicrobial activity of the thiosemicarbazone and semicarbazone derivatives of lapachol, which we synthesised for the first time, and tested against several clinically important microorganisms. Lapachol was also tested. Lapachol and its thiosemicarbazone derivative were also tested against human peripheral blood mononuclear cells (PBMCs).
SUBJECTS, MATERIALS AND METHODS
Synthesis -Lapachol was isolated from Tabebuia ochracea in a previous study by Zani et al. (1991) . Thiosemicarbazide (Sigma-Aldrich, Steinheim, Germany) was purified by crystallisation from water. Acetone (Vetec, RJ, Brazil), methanol (Sigma-Aldrich), semicarbazide hydrochloride (Sigma-Aldrich) and sodium hydroxide (Sigma-Aldrich, Steinheim, Germany) were used without further purification. Column chromatography was performed using silica gel 60G (70-230 mesh). Thin-layer chromatography (TLC) was executed on precoated TLC silica gel 60F 254 plates Merck (Darmstadt, Germany) and the spots were visualised under ultraviolet (UV) light at wavelengths of 254 and 366 nm after the plates had been sprayed with vanillin-H 2 SO 4 and heated at 120ºC for 10 min. Analytical high-pressure liquid chromatography (Shim-Pak prep SiL, 4 µm, 4.6 x 250 mm, 1 mL/min) was performed on a Shimadzu chromatography system equipped with an LC10AD pump and a UV detector set at λ 210 nm and λ 240 nm. Nuclear magnetic resonance (NMR) spectra were obtained on a Bruker DRX 400 spectrometer at 400 MHz using tetramethylsilane as an internal standard. Mass spectrometry (MS) results were acquired on a Thermo Finnigan LCQAdvantage spectrometer equipped with an electrospray ion (ESI) source. Solutions of the compounds at 200 μg/ mL in 1:1 MeOH-H 2 O were infused at a rate of 0.025 mL/min and positive and negative mass spectra were acquired with an m/z range of 50-1,000 daltons. The cone voltages were optimised for positive and negative ion analysis between 25-50 V. The capillary voltage was set at 4.5 kV in positive ion mode and 23.1 kV in negative ion mode. For the MS/MS experiments, the parent ion isolation width was 3.8 daltons and the normalised collision energy was set at 30% for both compounds. Fifty scans from 150-600 daltons were collected to generate the averaged spectra.
The X-ray diffraction data were collected on an Oxford-Diffraction GEMINI diffractometer (LabCri) using a graphite-enhanced MoKa radiation source (k = 0.71069 Å) at 293(2) K. The lapachol thiosemicarbazone twin crystal was mounted on a glass fibre and examined by structural X-ray diffraction methods. The data collection, integration and scaling of the reflections were performed with the CrysAlis suite programs (CrysAlis RED, Oxford Diffraction Ltd, version 1.171.32.38 and SCALE3 ABSPACK Scaling Algorithm, CrysAlis RED, Oxford Diffraction Ltd, version 1.171.32.38).
The final unit cell parameters were determined by fitting all the reflections. The structures were solved by direct methods with the program SHELXS-97 (Sheldrick 1997) and were refined by full-matrix least-squares methods against F 2 using SHELXL-97 (Sheldrick 1997 ). The positional and anisotropic atomic displacement parameters of the compound were refined for non-hydrogen atoms. Although all the hydrogen atoms could be identified in a Fourier difference map in the final model, the hydrogen atoms of lapachol thiosemicarbazone were included in the molecular model at stereo-chemical positions and were refined with the riding method. The molecular graphic was obtained from ORTEP (Johnson 1965 , Farrugia 1997 , Farrugia & Win 1999 . The studied material was endotoxin free.
Synthesis of lapachol thiosemicarbazone -A suspension of 10 mmol lapachol in 100 mL of water was added to 100 mL of 0.1 M NaOH, yielding a dark red solution. An aqueous-methanolic (50%) solution of thiosemicarbazide (12 mmol) was added dropwise to the above solution with constant stirring. The mixture was stirred for approximately 21 h, after which time the solution was neutralised with 10% HCl. The crude precipitated product was filtered and washed with cold water. The resulting solid was recrystallised from methanol and acetone (1:1), giving an orange crystalline thiosemicarbazone with a yield of 73% (Chikate et al. 2005) . The lapachol thiosemicarbazone was analysed by melting point analysis, MS, NMR and X-ray diffraction.
Synthesis of lapachol semicarbazone -A solution of 30 mL of 0.1 M NaOH was added to a suspension of 1 mmol lapachol, yielding a dark red solution. An aqueousmethanolic (50%) solution of semicarbazide (2.5 mmol) was added dropwise to the above solution with constant stirring. The mixture was stirred for approximately 23 h, after which time the solution was neutralised with 10% HCl. The crude product was filtered and washed with cold water. The resulting solid was purified by column chromatography (silica gel 70-230 mesh) using dichloromethane and ethyl acetate as eluents in mixtures with increasing polarity to give the semicarbazone, which was isolated as a yellow solid in a 13% yield (Chikate et al. 2005 The bacterial strains were maintained on brain heart infusion agar (Difco, USA). All the fungal strains were maintained on Sabouraud dextrose agar (Oxoid, Basingstoke, UK). The P. brasiliensis strains were maintained in yeast-peptone-dextrose (YPD).
Culture media and inocula -Mueller-Hinton broth (HiMedia, India) was prepared in accordance with the Clinical and Laboratory Standards Institute (CLSI) document M7-A6 (NCCLS 2003) for minimal inhibitory concentration (MIC) bacterial assays. Inocula of all the bacteria were prepared using the spectrophotometric method according to CLSI M7-A6 (NCCLS 2003) at a final concentration of 5 x 10 5 colony-forming unit /mL. The fungal cultures of the Candida species and C. gattii were freshly grown at 35ºC and the inoculum suspensions were prepared by the spectrophotometric method according to the CLSI document M27-A3 (CLSI 2008) with a final concentration of 1.5 ± 1.0 x 10 3 cells/mL for susceptibility tests. A weekly passage on solid YPD medium at 37ºC was performed to grow P. brasiliensis. Yeast cells in the exponential phase were collected aseptically with a sterile loop and resuspended in a tube containing 5 mL of sterile saline. Large aggregates were allowed to settle for several minutes and the supernatants were collected. The suspensions were diluted in synthetic RPMI medium (Sigma-Aldrich, St. Louis, MO, USA) containing L-glutamine and buffered to pH 7.0 with 0.165 M morpholine propanesulfonic acid (Sigma-Aldrich). The suspensions were prepared according to the CLSI document M27-A3 to obtain a final inoculum size suitable for each strain (CLSI 2008) . After homogenisation of the inocula by vortexing, the transmittance was measured at 520 nm and adjusted to 69-70% (Hahn & Hamdan 2000) .
Susceptibility test -Broth microdilution testing was performed in accordance with the guidelines presented in the CLSI documents M7-A6 (NCCLS 2003) for bacteria and M27-A3 for fungi (CLSI 2008) . The susceptibility to antimicrobial agents was determined by the microbroth dilution method and was performed in sterile flat-bottom 96-well microplates (Difco, Detroit, MI, USA).
The compounds were dissolved in dimethyl sulfoxide (DMSO) after the addition of Mueller-Hinton broth for the bacterial assays or RPMI for the fungal assays. Subsequently, serial dilutions were prepared using the corresponding media as the diluent, maintaining a constant volume of 1 mL in each tube. The compounds were tested at eight concentrations from 0.006-0.84 μmol/ mL. For each dilution, aliquots of 0.1 mL were added to the wells of the microplates.
For a growth and sterility control, media was used without the addition of extract or solvent. As a control for the toxicity of the solvent, a culture was inoculated with DMSO. Chloramphenicol (2.41 x 10 -3 to 0.31 μmol/ mL; Sigma-Aldrich) was used as a positive antibacterial control. Amphotericin B (3.25 x 10 -5 to 0.03 μmol/mL; Sigma-Aldrich) and trimethoprim/sulphamethoxazole (4.49 x 10 -3 to 2.3 μmol/mL; Roche, state of Rio de Janeiro, Brazil) were utilised as positive antifungal controls.
After the plates were prepared, the inocula of each bacterial and fungal strain were added and the plates were incubated at 37ºC for 24 h for the bacteria, 48 h for Candida spp, 72 h for C. gattii and 10 days for P. brasiliensis. Each test was performed in triplicate. The endpoints were determined visually by comparison of the samples with the drug-free control well. The MIC was defined as the lowest compound concentration at which the well was optically clear and was expressed in μmol/mL.
Sorbitol protection assays -The MICs were determined using P. brasiliensis strain Pb18 by the standard broth microdilution procedure described above. Duplicate plates were prepared: one contained lapachol thiosemicarbazone and 0.8 M sorbitol as an osmotic support and the other contained lapachol thiosemicarbazone alone. The MICs were determined after 10 days (Escalante et al. 2008) .
Human PBMCs -PBMCs were prepared using a modified version of the protocol previously described by Gazzinelli et al. (1983) . Briefly, PBMC samples were obtained via an agreement with the Minas Gerais Haematology and Haemotherapy Centre Foundation (protocol 105/2004). The PBMCs were obtained from healthy adult volunteers of both sexes by the centrifugation of heparinised venous blood over a Ficoll cushion (SigmaAldrich, St. Louis, MO). The mononuclear cells were collected from the interphase after Ficoll separation and were washed three times in RPMI-1640 medium before further processing. All the cultures were grown in RPMI-1640 medium (Sigma-Aldrich) supplemented with 5% (v/v) heat-inactivated, pooled AB (GIBCO/ BRL, Grand Island, NY) sera and 2 mM L-glutamine. An antibiotic/antimycotic solution containing 1,000 U/ mL penicillin, 1000 μg/mL streptomycin and 25 μg/mL fungizone (GIBCO/BRL, Grand Island, NY) was added to prevent fungal and bacterial contamination.
Analysis of cell viability -The PBMCs were cultured in 96-well plates at a density of 200,000 cells/well in a final volume of 0.2 mL/well. The plates were preincubated in a humidified 5% CO 2 /95% air atmosphere at 37ºC for 24 h to allow the cells to adapt prior to the addition of the test compounds. All the compounds were dissolved in DMSO prior to dilution. The toxicity was determined over a concentration range of 0.3-200 μg/ mL. All the cell cultures were incubated in a humidified 5% CO 2 /95% air atmosphere at 37ºC for 48 h. The cell viability was estimated by measuring the rate of the mitochondrial reduction of a yellow tetrazolium salt, 2-(3,5-diphenyltetrazol-2-ium-2-yl)-4,5-dimethyl-1-,3-thiazole bromide (MTT) (Sigma-Aldrich, St. Louis, MO], to insoluble purple formazan crystals (Mosmann 1983) . After incubation of the cultures with the test compounds, the MTT solution (0.020 mL at 5 mg/mL) was added to each well and the plates were incubated for 4 h. At the end of this incubation, the supernatant was removed and 0.04 M HCl in isopropyl alcohol (200 µL) was added to dissolve the formazan crystals. The optical densities were measured with a spectrophotometer at a wavelength of 590 nm. The results were normalised to the DMSO control (0.01%) and were expressed as the per cent inhibition of cell viability. The interactions between the compounds and the media were estimated based on the variations between the drug-containing medium and the drug-free medium to control for false-positive and false-negative results. The data were analysed using Prism 5.0 (GraphPad Software, Inc).
Statistical analyses -All the PBMC results were expressed as the mean ± standard deviation of three independent experiments that were performed at least in triplicate. These data were analysed using Student's t test for paired comparisons. A p value of less than 0.05 indicated statistical significance.
RESULTS
The reactions of lapachol (compound 1) with thiosemicarbazide and semicarbazide gave a thiosemicarbazone (compound 2) and a semicarbazone (compound 3) with yields of 73% and 13%, respectively (Fig. 1) . The ESI-MS data for compound 2 showed a positive ion peak at m/z 316, which was attributed to the quasi-molecular ion peak [M + H] + and the ESI-MS of compound 3 exhibited a negative ion peak at m/z 298, which was attributed to the quasi-molecular ion peak [M -H] -; these quasimolecular ion peaks correspond with the expected molecular weights of 315 and 299 g/mol for the compound 2 and the compound 3, respectively. The compound 2 had a melting point of 174.3-175.3ºC. The comparison of the 1 H spectra (Table I ) between lapachol and its derivatives (compounds 2 and 3) indicat- ed that the signals from the side-chain at C-3 were virtually unchanged. In addition, the N2-H chemical shifts at 14.94 and 14.26 in the spectra of 2 and 3 were indicative of conformations in which N2-H is hydrogen bonded to O-2. The N3-Ha and N3-Hb hydrogens of 2 were diastereotopic. The different chemical shifts likely result from a hydrogen bond between N3-Ha and N1, indicating that the same conformation that has been suggested in solution is found in the solid state.
Changes were predominantly observed in the 13 C NMR spectrum (Table I) . Shielding effects were observed at C-1 [δ C 129.53 (2) and 129.21 (3)], C-4 [δ C 163.62 (2) and 163.00 (3)] and C-3 [δ C 117.39 (2) and 117.23 (3)] with the carbonyl group of lapachol being replaced with an imine group (C-1), a hydroxyl group (C-4) or a C3-C4 double bond in the obtained products. Changes in the values of the aromatic ring and a deshielding effect at C-2 [δ C 180.44 (2) and 181.00 (3)] compared with lapachol (δ C 154.98) suggested the formation of a carbonyl group at C-2. The 13 C signals related to the thiosemicarbazone (compound 2) and semicarbazone (compound 3) moieties were observed at δ C 179.51 (C = S) for 2 and at δ C 155.45 (C = O) for 3 ( Table I ). The COSY, HMQC and HMBC spectra were used to confirm the structures and to unambiguously assign the chemical shifts for all the hydrogen and carbon atoms of 2 and 3 ( Table I) .
The presence of the thiosemicarbazone and semicarbazone moieties at C-1 was confirmed by the observation of N2-H•••O1 hydrogen bonds in (2) and (3) and by the heteronuclear long-range couplings of the hydrogen and carbon atoms that were revealed by the cross-peaks in the HMBC spectra. These cross-peaks corresponded to the spin-spin interactions of H-11 [δ H 3.27 (2) and 3.26 Table II . Selected intramolecular bond distances and angles in the structure are presented in Table  III . The bond lengths and angles for the lapachol moiety are in good agreement with the values that were reported for Hooker's "lapachol peroxide" (Júnior et al. 2009 ). The most significant differences are the C-O bonds. The C-O distance varies from 1.364-1.431 Å for the single bonds and from 1.209-1.227 Å for the double bonds in Hooker's lapachol structure. In lapachol thiosemicarbazone, the C4-O2 (1.350(2) Å) single bond is shorter and the C2-O1 [1.236(2) Å] double bond is longer. The bond distances and angles in the thiosemicarbazone framework are similar to the bonds and angles in other thiosemicarbazones (Beraldo et al. 2001 , Lessa et al. 2010 .
Lapachol thiosemicarbazone adopts the E conformation with respect to the N2-C16 bond in the solid state. A weak intramolecular N2-H•••O1 hydrogen bond (Table  IV) is present in the structure, but is not likely to facilitate rotation around the N2-C16 bond. The same conformation occurs in 2 in a DMSO solution, as was discussed earlier.
In the compound packing, weak intermolecular O2-H•••S1 and N3-H•••O2 hydrogen bonds result in the formation of linear arrangements in the solid state (Fig. 3) . The lapachol thiosemicarbazone and semicarbazone derivatives were tested against five pathogenic bacteria (E. coli, S. aureus, P. aeruginosa, S. typhimurium and E. faecalis). The most effective antimicrobial activities were observed against two pathogenic Gram-positive bacteria, S. aureus and E. faecalis (Table V) . These compounds were inactive against Gram-negative bacteria. The lapachol thiosemicarbazone and semicarbazone derivatives had MICs of 0.10 μmol/mL against S. aureus and 0.05 μmol/mL against E. faecalis. Lapachol inhibited the growth of S. aureus and E. faecalis at a concentration of 0.52 μmol/mL. The semicarbazide and thiosemicarbazide reagents were tested against five pathogenic bacteria and were active against E. faecalis, inhibiting its growth at a concentration of 0.83 and 0.69 μmol/mL, respectively (Table V) .
Lapachol was tested against opportunistic Candida sp., C. gattii and P. brasiliensis. It had superior activity only against P. brasiliensis; the MIC was 0.13 μmol/ mL for most of the isolates and 0.26 μmol/mL for P. brasiliensis 01.
The lapachol thiosemicarbazone derivative exhibited the best antifungal activity, with MICs ranging from 0.01-0.10 μmol/mL for the isolates of P. brasiliensis. The lapachol semicarbazone derivative was less active than the thiosemicarbazone derivative against the P. brasiliensis isolates (MICs 0.42 vs. 0.84 μmol/mL, respectively). C. albicans and C. tropicalis were resistant to the thiosemicarbazone and semicarbazone derivatives at the tested concentrations. C. gattii was susceptible to the thiosemicarbazone and semicarbazone derivatives, with MICs of 0.10 and 0.21 μmol/mL, respectively. The semicarbazide and thiosemicarbazide reagents were inactive against all fungi tested except P. brasiliensis isolates, the growth of which was inhibited by the thiosemicarbazide reagent at a concentration of 1.37 μmol/mL.
In this study, the lapachol thiosemicarbazone derivative had the greatest activity against P. brasiliensis; therefore, its effect on the fungal cell wall was determined using the sorbitol assay. A distinctive feature of specific inhibitors of fungal cell wall synthesis is that the antifungal effect is reversed in media containing an osmotic stabiliser such as sorbitol (Frost et al. 1995) . However, the lapachol thiosemicarbazone derivative did not affect the fungal cell wall because the MIC for P. brasiliensis did not change upon the addition of sorbitol to the culture medium.
Compared with the control (0.01% DMSO), the lapachol-derived thiosemicarbazone did not reduce cell viability over the concentration range of 9.52 x 10 -4 to 0.32 μmol/mL (0.3-100 μg/mL), but at 0.64 μmol/mL (200 μg/ mL), this compound significantly reduced cell viability, indicating cytotoxicity (Fig. 4) . The MICs for this compound against the isolates of P. brasiliensis were in the range of 0.10-5.40 x 10 -3 μmol/mL (31.2-1.7 μg/mL). For E. faecalis and S. aureus, the MICs were between 0.10-0.05 μmol/mL (between 31.2-15.6 μg/mL). These results indicate that the lapachol-derived thiosemicarbazone is not cytotoxic against normal cells at the concentrations that were active against fungi and bacteria. Conversely, lapachol had a biphasic dose-response curve, exhibiting toxicity at both the maximal concentration of 0.83 μmol/ mL (200 μg/mL) and the intermediate concentration of 0.01 μmol/mL (3 μg/mL). At 0.01 mmol/mL (3 mg/mL), there was a significant reduction in cell viability compared with the control (0.01% DMSO). At the other tested concentrations, this compound was not toxic. The MICs for lapachol against P. brasiliensis and the two tested bacterial strains were in the range of 0.52-0.13 μmol/mL (124-31.2 μg/mL) and 0.52-0.06 μmol/mL (125-15.6 μg/ mL), respectively, and no toxicity was observed against the PBMCs at these concentrations.
Supplementary material -CCDC reference 844492 for 2 contains the supplementary crystallographic data. These data can be obtained free of charge from the CCDC via ccdc.cam.ac.uk/data_request/cif.
DISCUSSION
In this study, we determined the MICs for lapachol and its derivatives against clinical pathogens and the results indicate that these compounds were active against C. gattii, several isolates of P. brasiliensis and Grampositive bacteria, including S. aureus and E. faecalis. The lapachol semicarbazone derivative had weaker antimicrobial activity than the lapachol thiosemicarbazone. Although semicarbazones have extensive pharmacological profiles, many activities are lost or diminished by the substitution of the sulphur for oxygen (Beraldo 2004) .
The activity against E. faecalis is promising because this bacterium has adapted such that it can survive and prevail in the bacterial flora that colonise the gastrointestinal tract of critically ill, immunocompromised and/ or neutropenic patients. Consequently, the number of severe enterococci infections is increasing, especially in tertiary hospitals (McBride et al. 2007 ). The thiosemicarbazone and semicarbazone derivatives of lapachol were two-fold more active than chloramphenicol against E. faecalis and had MICs similar to that of chloramphenicol when tested against S. aureus. S. aureus causes staphylococcal infections and following the introduction of methicillin, there has been a steady increase in methicillin-resistant S. aureus isolates that are resistant to vancomycin, even in Brazil (Palazzo et al. 2005) . The initial studies, conducted at the Department of Antibiotics at the Federal University of Pernambuco in 1973, demonstrated the robust activity of lapachol against Gram-positive bacteria (Lima & Weigert 1972 , Nagata et al. 1998 ). These studies revealed that lapachol was active against Helicobacter pylori, Staphylococcus, Streptococcus, Enterococcus, Bacillus and Clostridium, with MICs ranging from 1,560-25,000 μg/mL (Almeida 2009 (Beraldo 2004) .
In this study, the lapachol-derived thiosemicarbazone had superior antimicrobial activity against clinical isolates of P. brasiliensis. Our data indicated that the lapachol thiosemicarbazone derivative was more active than sulphonamides, the first class of drugs available for treating patients with PCM. This finding is important because the use of sulphonamides for more than two years may be required to treat PCM. Moreover, there is increasing concern about drug toxicity and treatment cost (Brummer et al. 1993 , Paniago et al. 2003 , Travassos et al. 2008 .
The lapachol-derived semicarbazone and thiosemicarbazone also exhibited antimicrobial activity against C. gattii (Table V) . These results are significant because this pathogenic yeast primarily infects healthy individuals and has a high mortality rate (Chaturvedi et al. 2005) . Amphotericin B, alone or in combination with flucytosine, remains the standard antifungal therapy for these infections, despite the toxicity of both drugs (Lima & Weigert 1972) . Other drugs, such as fluconazole and itraconazole, are used as oral maintenance or consolidation therapy for cryptococcosis (Perfect & Casadevall 2002) . However, resistance to fluconazole has arisen in recent years (Sabbatani et al. 2004 ).
Lapachol was previously tested against C. albicans and Cladosporium cucumerinum on silica gel plates and it exhibited antimicrobial activity at minimal concentrations of 0.04 and 2.48 x 10 -3 μmol/mL, respectively (Gafner et al. 1996) . However, the MICs for lapachol were not determined. In addition, it has been reported that analogues of furanonaphthoquinone from Tecoma ipe have MICs of 1-8 μg/mL against several pathogenic fungi (Nagata et al. 1998) , indicating a therapeutic potential for naphthoquinones against fungi.
Lapachol and its thiosemicarbazone derivative had dramatic antifungal activity. Lapachol is known for its antimicrobial activity, but its thiosemicarbazone derivative has never been described. In this study, this derivative was found to be superior to lapachol in terms of antifungal activity.
Our data demonstrate that these derivatives were less toxic than lapachol, which exhibited a biphasic response with toxicity at higher concentrations and hormesis at 0.01 μmol/mL (3 μg/mL). Hormesis describes a dose-response curve with opposite effects at low doses vs. high doses (Hoffman 2009 ). Therefore, the in vitro cytoxicity assays performed using immune system cells revealed a potentially greater immunotoxicity for lapachol than for its derivatives.
The MICs for the lapachol-derived thiosemicarbazone against pathogenic bacteria (S. aureus and E. faecalis) and fungi (mainly P. brasiliensis) indicate that these compounds are excellent choices for the development of novel drugs to treat microbial infections. Further studies are necessary to verify the effectiveness of these compounds in treating infections caused by microorganisms.
